IM-250

IM-250
Names
	IUPAC name (S)-2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
Identifiers
CAS Number	2305750-23-4 ;
3D model (JSmol)	Interactive image;
PubChem CID	138523647;
	InChI InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3 Key: JDZTWDISDHLKCR-UHFFFAOYSA-N;
	SMILES CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=C(C=CC(=C3)F)F)S(=N)(=O)C;
Properties
Chemical formula	C20H19F2N3O2S2
Molar mass	435.51 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

IM-250 is an anti-herpetic drug candidate^[1] developed by Innovative Molecules Gmbh.^[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.^[3]

Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.^[4]

References

^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.
^ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.
^ "Small molecule fights active and latent herpes infections in rodents".
^ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.

[2] "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.

[3] "Small molecule fights active and latent herpes infections in rodents".

[4] Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.

[1]

[2]

[3]

[4]

See also

References